Shire hit by decline in full year operating income

Pharmaceuticals company Shire took a hit on Thursday after admitting that on a US GAAP basis its 2012 operating income fell 14 per cent as it revealed that sales of its Adderall XR product had dropped 19 per cent.

Pharmaceuticals company Shire took a hit on Thursday after admitting that on a US GAAP basis its 2012 operating income fell 14 per cent as it revealed that sales of its Adderall XR product had dropped 19 per cent.

In an otherwise upbeat set of results, the company said sales of Adderall has fallen to $429m, primarily due to lower prescription volumes following the approval of a new generic version of the product in the second quarter of 2012. Reported product sales were also affected by the accounting for the settlement of the Impax Laboratories litigation.

Operating income, on a US GAAP (generally accepted accounting principles) basis, declined from $1,109m to $949m year-on-year, primarily resulting from charges to impair intangible assets for its Resolor product in

the EU ($198m) in 2012. The impairments were due to lower actual and projected performance for the product given the increasingly challenging European reimbursement environment, the group said.

Furthermore, a charge of $58m also negatively affected operating income, which related to the agreement in principle with the US government to resolve a previously disclosed civil investigation.

However, the group stressed its confidence in the year ahead and said it is in a strong position following what it described as a strong set of results.

Full year product sales rose 12% to $4,407m, with total revenues up 10% at $4,681m. In the fourth quarter product sales rose 5.0%, with total revenues also up 5.0% at $1,201m. Product sales fell 35% to $82m during the period.

Angus Russell, Chief Executive Officer, said: "It's been another strong year for Shire with 12% growth in product sales and 14% growth in non-GAAP earnings, which have driven particularly strong cash generation. While delivering strong financial results, we continue to invest in our emerging late stage R&D [research & development] pipeline.

"Our ADHD portfolio is performing very well in a growing global market and we see further growth going forward. The positive opinion received from the European regulators for Elvanse is a significant milestone and we're now preparing for country launches in some of the largest markets in Europe.

"Our late stage R&D pipeline now holds the prospect of future growth from LDX (the active ingredient in Vyvanse) in major depressive disorder, binge eating disorder and negative symptoms of schizophrenia. Our intrathecal programs are also progressing well as we plan the next clinical trials for Hunter CNS and Sanfilippo A and continue to enrol MLD patients into the ongoing Phase 1/2 trial. A phase 2b study of SPD602, our iron chelating product, is underway and headline results are expected later this year.

"Shire is in great shape, with the current business performing well, a promising pipeline of new growth opportunities, and the strategy in place to deliver an exciting future. As we look forward to the year ahead, we expect our financial results to show further growth in line with current consensus earnings expectations for 2013(1)."

The share price fell 3.4% to 2,072p by 13:00.

NR

Recommended

The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
23 Jan 2023
The top ten dividend stocks in the FTSE 250
Share tips

The top ten dividend stocks in the FTSE 250

The average FTSE 250 dividend yield is around 4%, but many stocks yield much more. Rupert Hargreaves picks the best FTSE 250 stocks for income investo…
17 Jan 2023
The top funds to invest in
Funds

The top funds to invest in

As market volatility and recessionary fears continue, here are the most popular funds, stocks and trusts investors are putting their money into accord…
5 Jan 2023
Investing trends to watch out for in 2023: what analysts say
Investment strategy

Investing trends to watch out for in 2023: what analysts say

What are sensible strategies for high inflationary times? We ask analysts to find out.
22 Dec 2022

Most Popular

House prices could fall 30%. Should investors be worried about a repeat of 2008?
Investments

House prices could fall 30%. Should investors be worried about a repeat of 2008?

Some analysts are predicting that house prices could fall as much as 30%, which, when compared to the fact that prices have jumped 28% since April 201…
24 Jan 2023
Will energy prices go down in 2023?
Personal finance

Will energy prices go down in 2023?

Wholesale gas prices are on a downward trajectory, but does this mean lower energy bills later this year?
27 Jan 2023
Council tax increases 2023 – how much more will you pay?
Tax

Council tax increases 2023 – how much more will you pay?

Your council tax bill will go up in April - we reveal the councils that have confirmed what this year’s increase will be.
23 Jan 2023